TAMARIND MARIE KEATING ARNP MPH NPI 1508012568

NPI Details

Tamarind Marie Keating, ARNP, MPH is a nurse practitioner in Bend, OR. The provider is (1) A registered nurse provider with a graduate degree in nursing prepared for advanced practice involving independent and interdependent decision making and direct accountability for clinical judgment across the health care continuum or in a certified specialty. (2) A registered nurse who has completed additional training beyond basic nursing education and who provides primary health care services in accordance with state nurse practice laws or statutes. Tasks performed by nurse practitioners vary with practice requirements mandated by geographic, political, economic, and social factors. Nurse practitioner specialists include, but are not limited to, family nurse practitioners, gerontological nurse practitioners, pediatric nurse practitioners, obstetric-gynecologic nurse practitioners, and school nurse practitioners. Tamarind Marie Keating, ARNP, MPH NPI is 1508012568. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a female.

The provider's business location address is:

2500 NE NEFF RD
BEND, OR
ZIP 97701-015
Phone: (541) 706-5800

The NPI 1508012568 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, potassium chloride, per 2 meq (HCPCS:J3480)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, cisplatin, powder or solution, 10 mg (HCPCS:J9060)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or (HCPCS:G2212)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Ferritin (blood protein) level (HCPCS:82728)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Drawing of blood for a medical problem (HCPCS:99195)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Iron level (HCPCS:83540)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Transferrin (iron binding protein) level (HCPCS:84466)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Unclassified drugs (HCPCS:J3490)
• Manual urinalysis test with examination using microscope, automated (HCPCS:81001)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Thyroxine (thyroid chemical), free (HCPCS:84439)
• Collection of blood sample from implanted device (HCPCS:36591)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Collection of blood sample from central venous tube (HCPCS:36592)
• Injection of drug or substance into vein (HCPCS:96374)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r (HCPCS:U0003)
• Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within (HCPCS:U0005)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)

The enumeration date for this NPI number is 8/11/2008 and was last updated on 8/19/2025.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.